中晚期PHC患者TACE术前后血清Th1/Th2细胞因子AFP水平的变化及意义

doi:10.3969/j.issn.1006-6233.2018.06.039

Abstract
Figure/Table
References
Related Citation (6)

Download: PDF (1324 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the levels changes of serum Th1/Th2 cytokines and AFP in patients with advanced hepatocellular carcinoma (PHC) before and after transcatheter arterial chemoembolization (TACE) and their clinical significance. Methods: 95 cases of PHC patients hospitalized in our hospital were divided into the TACE group (n=58, given TACE treatment) and the venous group (n=37, given intravenous chemotherapy). The lesion reduction degree and the levels of serum Th1/Th2 cytokines and AFP before and after TACE were compared between the two groups. Results: The total reduction rate of lesion in the TACE group was significantly higher than that in the venous group (P<0.05). The serum AFP level, the AFP positive rate and the levels of serum interleukin-4 (IL-4) and interleukin-10 (IL-10) were significantly decreased after treatment in the two groups (P<0.05) while the levels of interferon-γ (IFN-γ) and interleukin-2 (IL-2) were significantly increased (P<0.05). The levels changes of serum AFP and Th1/Th2 cytokines in the TACE group were higher than those in the venous group (P<0.05). The positive expression rate of IL-10 in the TACE group was significantly lower than that in the venous group (P<0.05). Conclusions: TACE treatment can effectively control the disease condition of advanced PHC and regulate Th1/Th2 balance disorders, and the levels of serum Th1/Th2 cytokines and AFP can be used as important indicators for efficacy evaluation.

Key words： Primary hepatocellular carcinoma TACE Th1/Th2 cytokines Alpha fetoprotein

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Biyu
	WANG Luying
	et al

Cite this article:

WANG Biyu,WANG Luying,et al. Change and Significance of Levels of Serum Th1/Th2 Cytokines and AFP before and after TACE in Advanced PHC Patients[J]. HeBei Med, 2018, 24(6): 1028-1031.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.06.039 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I6/1028

[1] 林武华.肝动脉栓塞化疗联合CIK细胞免疫法对原发性肝癌的治疗作用观察[J].解放军医学杂志,2015,40(12):1021~1022.
[2] 王哲,何德山,任柯.中晚期原发性肝癌患者的治疗方案对比研究[J].中国现代普通外科进展,2016,19(1):69~72.
[3] 王甦,黄一枫,刘佳,等.TACE治疗原发性肝癌对肝功能的影响及相关因素的研究[J].胃肠病学和肝病学杂志,2016,25(8):881~884.
[4] 中国抗癌协会肝癌专业委员会.原发性肝癌诊断标准[J].中华肝脏病杂志,2000,8(3):135.
[5] 王鑫,周宁新,段伟宏.原发性肝癌临床分期的对比探讨[J].现代生物医学进展,2014,14(8):1576~1579.
[6] 赵春华,周文峰,陈维华,等.甲胎蛋白在原发性肝癌首诊中的价值[J].临床肝胆病杂志,2013,29(9):698~701.
[7] 娄玥.射频消融术联合肝动脉介入术治疗原发性肝癌的临床观察[J].中国基层医药,2015,22(21):3214~3216.
[8] 冯众一,高鹏,谭文翔,等.原发性肝癌TACE介入治疗前后血清VEGF和bFGF水平变化及临床意义[J].中国现代普通外科进展,2015,18(2):154~155.
[9] 郭娟,马刚.原发性肝癌血清AFP、AFP-L3表达与CT影像的关系[J].贵州医药,2016,40(6):626~628.
[10] 贾蓓,刘建宁,张岁,等.DC-CIK对肝癌患者免疫平衡的影响及临床疗效研究[J].河北医科大学学报,2016,37(4):440~444.
[11] 程广霞,李建志,张俊,等.原发性肝癌血清细胞因子检测的临床意义[J].中国现代普通外科进展,2016,19(12):990~991.
[12] 卢庭婷,梁惠萍,李致忠,等.HLA-DQB1等位基因多态性及Th1/Th2细胞相关因子与广西瑶族肝癌家族聚集性的相关性[J].中国免疫学杂志,2016,32(9):1262~1267.
[13] 戎冬文,王慧宇,贾军梅,等.射频消融治疗前后肝癌患者外周血免疫细胞亚群及Th1/Th2细胞因子的变化[J].中国肿瘤临床与康复,2017,24(12):1431~1434.